Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ: LEXX )

2.230 +0.020 (+0.90%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 96,297
Open 2.220
Bid (Size) 2.040 (30)
Ask (Size) 2.250 (1)
Prev. Close 2.210
Today's Range 2.150 - 2.240
52wk Range 1.200 - 6.850
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Lexaria's Registered GLP-1 Study #4 Begins Dosing
Via ACCESSWIRE
Lexaria Forms New Scientific Advisory Board
Via ACCESSWIRE

Performance

YTD
+72.87%
+72.87%
1 Month
+3.24%
+3.24%
3 Month
-29.43%
-29.43%
6 Month
-15.85%
-15.85%
1 Year
+72.87%
+72.87%

More News

Read More
Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience
Via ACCESSWIRE
Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5
Via ACCESSWIRE
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Highlights Expanding Opportunities in GLP-1 Drug Market and Strategic Focus on DehydraTECH Integration
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Highlights Expanding Opportunities in GLP-1 Drug Market and Strategic Focus on DehydraTECH Integration
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property
Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs
Via ACCESSWIRE
Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled
Via ACCESSWIRE
ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria’s 12-Week GLP-1, Diabetes Animal Study
Via ACCESSWIRE
Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study
Via ACCESSWIRE
Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss
Via ACCESSWIRE
Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments
Via ACCESSWIRE
Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
Via TheNewswire.com
Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study
Via ACCESSWIRE
Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
Via TheNewswire.com
Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study
Via ACCESSWIRE
Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing
Via ACCESSWIRE
Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via TheNewswire.com
Topics Regulatory Compliance
Exposures Legal Regulatory
Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Via ACCESSWIRE
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Subject Dosing in Human Pilot Study #3 Evaluating Oral DehydraTECH-Processed Tirzepatide
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Update on Growth of GLP-1 Market Space, Notes Potential for Oral Delivery
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Updates Current GLP-1 Market
Via ACCESSWIRE
HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Strengthen Executive Team in Anticipation of ‘Strong Growth’ into 2025
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Lexaria Appoints Michael Shankman as Chief Financial Officer
Via ACCESSWIRE
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.